Advertisement
News
Advertisement

Definiens and Metamark Enter Multi-Year Deal for Prostate Cancer Prognostic Test

Wed, 11/20/2013 - 9:30am
Business Wire

Definiens, the global leader in image analysis for digital pathology and diagnostics, and Metamark Genetics, a privately-held biotechnology company developing novel tests aimed at improving cancer care, today announced a multi-year agreement covering use of the Definiens image analysis solution for the ProMark™ prostate cancer prognostic test. ProMark™ is a multiplex immunofluorescence test that integrates Definiens’ core image analysis platform, Cognition Network Technology®, to automatically classify prostate tumor “regions of interest” and quantify novel proteomic markers expressed in prostate biopsies. Metamark recently announced positive ProMark™ clinical validation results, and plans to make the test available to pathologists, urologists and their patients in early 2014. ProMark™ is designed to help physicians make informed treatment recommendations for prostate cancer patients by identifying low risk patients who may benefit from active surveillance rather than aggressive treatment. Definiens’ software platform will be used to support Metamark’s fully automated analysis of clinical prostate cancer biopsies.

“It is a privilege to work with Metamark as they bring their innovative prostate cancer prognostic test, ProMark™, to market. The incorporation of Definiens’ automated image analysis platform into this test highlights the importance of objective image analysis in the prognosis and treatment of cancer,” said Thomas Heydler, CEO of Definiens.

“We have worked well with the Definiens team and are pleased to extend our collaboration as we commercialize ProMark™,” said Shawn Marcell, CEO of Metamark. “Incorporating Definiens software in the analysis platform has allowed us to accelerate development and validation of ProMark™ and generate clinical data that has the potential to revolutionize the treatment of prostate cancer.” About Definiens Definiens is the leading provider of image analysis and data mining solutions for life science, tissue diagnostics and clinical digital pathology. Definiens' technology provides detailed biomarker readouts from slide images and enables the correlation of this information with other key clinical or genomic information. Definiens helps pharmaceutical and biotechnology companies, research institutions, clinical service organizations and pathologists generate new knowledge and supports improved decisions in research, diagnostics and therapy.

Definiens’ vision is to open new fields of research, to contribute to development of personalized medicine and to significantly improve the quality of patients' lives. Definiens is headquartered in Munich, Germany and has its North American headquarters in Carlsbad, CA. Further information is available at www.definiens.com.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading